Sort
15,273 grants matching “antimicrobial resistance”
Disease Modeling of Influenza and Other Emerging Respiratory Viral Pathogens
$856,485Heinrich Feldmann · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
RNA: New Antimicrobial Strategies
$856,193Adrian Ferre-D'amare · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL
Preclinical Development of SB 44 as an Orally Bioavailable Anti-HBV Agent
$856,160Radhakrishnan P Iyer · Spring Bank Technologies, Inc. · R01 · FY2014 · AI
New Tricks for 'Old' Drugs: PK/PD of Polymyxin Nonantibiotic Combinations
$855,749Jian Li · Monash University · R01 · FY2017 · AI
Optimizing Inhibitors of T. gondii ENR
$854,765Rima L McLeod · University Of Chicago · U01 · FY2012 · AI
Novel Therapeutics for Biodefense
$854,748Paratek Pharmaceuticals · R43 · FY2005 · AI
DEVELOPMENT OF BROAD SPECTRUM ANTIVIRALS
$853,295Matthew Duchars · Unither Virology, Llc · N01 · FY2016 · AI
Epithelial biology: morphogenesis and damage signaling
$853,020David Bilder · University Of California Berkeley · R35 · FY2024 · GM
Task A25: New Strain Testing and PKPD Studies for Therapeutics in Murine Models of Bacterial Thigh Infections
$852,140Lynn Miesel · · N01 · FY2018 · AI
CAREER: The Molecular Basis of Persister Cell and Biofilm Formation by the E. Coli Protein MqsR
$852,025Rebecca Page · Brown University · · FY2010 · BIO
Task C02: Non-GMP manufacturing of a compound with activity against gram negative bacteria
$852,008Melissa Allard · Albany Molecular Research, Inc. · N01 · FY2019 · AI
Defining functional humoral correlates of immunity to guide vaccine design
$850,980Galit Alter · Massachusetts General Hospital · R01 · FY2021 · AI
Advanced Development of Therapeutic Products for Antibiotic Resistant Bacteria
$850,507Urs Ochsner · Crestone, Inc. · N01 · FY2021 · AI
Novel mycobacterial translocase I inhibitors - a new class of anti-TB drugs
$850,410Venkata M Reddy · Sequella, Inc. · R44 · FY2010 · AI
Antimicrobial resistant E. coli before and after California Senate bill 27 (ARES): a natural experiment
$849,858Sara Tartof · Kaiser Foundation Research Institute · R01 · FY2017 · AI
A blind source separation approach for deconvolution of bulk transcriptional data leads to early detection of ATF cell-states in complex bacterial populations, in vitro and in vivo
$849,504Tim Van Opijnen · Broad Institute, Inc. · U19 · FY2023 · AI
Establishing the Genetic Basis of Altered Drug Responses in Mycobacterium tuberculosis
$849,354Sarah M Fortune · Harvard Medical School · U19 · FY2021 · AI
Exploration, conservation, & development of marine biodiversity in Fiji
$848,058Mark E Hay · Georgia Institute Of Technology · U01 · FY2012 · TW
Novel, Non-Toxic Ocular Antiseptic For Intravitreal Injection Therapy
$847,954Stephen J Smith · Irenix Medical, Inc. · R44 · FY2020 · EY
NIH Director's Pioneer Award
$847,500Evgeny Nudler · New York University School Of Medicine · DP1 · FY2009 · OD
Strengthening Integrated Surveilance of Antimicrobial Resistance Globally
$847,500Awa Aidara-Kane · World Health Organization · U01 · FY2010 · FD
NIH Director's Pioneer Award
$847,500Evgeny Nudler · New York University School Of Medicine · DP1 · FY2010 · OD
Genetic analysis of toxinogenesis of Vibrio cholerae
$847,498John J Mekalanos · Harvard Medical School · R37 · FY2021 · AI
Genetic analysis of toxinogenesis of Vibrio cholerae
$847,498John J Mekalanos · Harvard Medical School · R37 · FY2022 · AI
Genetic analysis of toxinogenesis of Vibrio cholerae
$847,498John J Mekalanos · Harvard Medical School · R37 · FY2019 · AI